By Kevin E. Noonan — Earlier this month, the Federal Circuit affirmed a decision by the Patent Trial and Appeal Board (PTAB) that the claims of U.S. Reissue Patent No. RE38,551 challenged in inter partes review were not unpatentable for obviousness, in Mylan Pharmaceuticals Inc. v. Research Corporation Technologies, Inc. The claims of the ‘551 reissue patent were directed to compounds for treating epilepsy (as well as other central nervous system disorders). The compounds have the generic structure: Ar-CH2NH-C(O)-HC(CH2Q)-NH-C(O)-Q1 where Ar is a phenyl group optionally substituted with a halo group; Q is a lower alkoxy substituent; and Q1 is…
View the original article here: Mylan Pharmaceuticals Inc. v. Research Corporation Technologies, Inc. (Fed. Cir. 2019)
The article was originally posted on Patent Docs.
Each article is copyrighted to their original authors. We do not own any rights to the news or the images used. Whilst every care is taken to ensure that the news posts published are accurate, we cannot guarantee the authenticity of the news article on every occasion. There’s no copyright infringement intended. The news is for informational purposes only and does not provide legal advice.